Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 20;3(5):e000368.
doi: 10.1136/esmoopen-2018-000368. eCollection 2018.

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Matthias Preusser  1 , Leticia De Mattos-Arruda  2 , Marc Thill  3 , Carmen Criscitiello  4 , Rupert Bartsch  5 , Thomas Ruhstaller  6 , Evandro de Azambuja  7 , Christoph C Zielinski  8
Affiliations
Review

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

Matthias Preusser et al. ESMO Open. .

Erratum in

Abstract

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.

Keywords: CDK4/6 inhibitors; HR-positive breast cancer; breast cancer; endocrine resistance; endocrine therapy; metastatic breast cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MP: research support from Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche and honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca and AbbVie. MT: advisory role at: Amgen, AstraZeneca, Celgene, Eisai, Genomic Health, Lilly, Neodynamics, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, SurgicEye, Tesaro, Teva. Speaker engagements and travel support: Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Eisai, Genomic Health, Medtronic, Myriad, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, Teva. Manuscript fees: Roche, Celgene. Trial funding: Genomic Health. RB: advisory role: Eli-Lilly, Novartis, Pfizer; Lecture honoraria: Eli-Lilly, Novartis, Pfizer; research support: Novartis; Travel support: Pfizer. TR: advisory role for: Lilly, Roche, Novartis, Pfizer, AstraZeneca; Travel support: Roche, Amgen. EdA: honoraria and advisory board: Roche/GNE; travel grants: Roche/GNE and GSK/Novartis; research grant: Roche/GNE. CCZ: Honoraria from Ariad, Novartis, Boehringer-Ingelheim, Roche and AstraZeneca.

Figures

Figure 1
Figure 1
Cell cycle progression in cancer and the role of cyclin-dependent kinases (CDK)4/6 inhibitors. Adapted with permission of John Wiley & Sons from: Murphy. Permission conveyed through Copyright Clearance Center.
Figure 2
Figure 2
Cross-talk between oestrogen (ER) and epidermal growth factor receptor (EGFR)/insulin-like growth factor 1 receptor (IGF-1R) signalling pathway and cyclin-dependent kinase (CDK)4/6 function. Adapted with permission from Springer Nature: Di Cosimo S and Baselga J. Copyright 2010. HER2-1, human epidermal growth factor receptor 2; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase.
See this image and copyright information in PMC

References

    1. Cardoso F, Costa A, Senkus E, et al. . 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017;28:3111 10.1093/annonc/mdx036 - DOI - PMC - PubMed
    1. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233–47. 10.1146/annurev-med-070909-182917 - DOI - PMC - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74. 10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 2016;18:17 10.1186/s13058-015-0661-5 - DOI - PMC - PubMed
    1. Asghar U, Witkiewicz AK, Turner NC, et al. . The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015;14:130–46. 10.1038/nrd4504 - DOI - PMC - PubMed